🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Aranzazu Fernández-Martínez

University of North Carolina at Chapel Hill

ORCID: 0000-0002-2311-4356

Also affiliated with Institut Gustave Roussy, Research Institute Hospital 12 de Octubre, UNC Lineberger Comprehensive Cancer Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination”.

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination

JAMA Oncology(2024)10.1001/jamaoncol.2023.6038

N/A

0.819DataRank · unranked

21 citations

Vera J. Suman, Souzan Sanati, Kiran Vij, Meenakshi Anurag, A. Marilyn Leitch +25 more

Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials

Nature Communications(2023)10.1038/s41467-023-42635-2

N/A

0.434DataRank · unranked

17 citations

Aranzazu Fernández-Martínez, David Venet, Françoise Rothé, Katherine A. Hoadley, Joel S. Parker +17 more

Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

ESMO Open(2024)10.1016/j.esmoop.2024.102388

N/A

0DataRank · unranked

18 citations

Tomás Pascual, Fara Brasó‐Maristany, Laia Paré, Olga Martínez‐Sáez, Javier Cortés +15 more

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)

Annals of Oncology(2024)10.1016/j.annonc.2024.12.010

N/A

0DataRank · unranked

3 citations

Maki Tanioka, Sung Gwe Ahn, Paola Zagami, Tomás Pascual, Mattia Rediti +18 more

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor–Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination

UNC Libraries(2024)10.17615/41px-cd59

N/A

0DataRank · unranked

1 citations

Travis Dockter, Amy Tiersten, Matthew J. Ellis, Kelly K. Hunt, Wajeeha Razaq +25 more